Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Phase 2
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT00823680
A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT00823992
A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 66
- Registration Number
- NCT00817687
A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 145
- Registration Number
- NCT00817518
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- Drug: RO1507Drug: pemetrexelDrug: mFOLFOX6
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT00811993
A Study of Taspoglutide in Type 2 Diabetic Patients
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00811460
A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT00810277
- Locations
- 🇫🇮
Kanta-Hämeen Keskussairaala ; Reumatologia, Hämeenlinna, Finland
🇫🇮Kiljavan Lääketutkimus Oy, Hyvinkää, Finland
🇫🇮Kanta-Hämeen keskussairaala; Riihimäen aluesairaala Reumapoliklinikka, Riihimäki, Finland
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT00811135
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00809705
A Study of RO4917523 in Patients With Treatment Resistant Depression
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT00809562
© Copyright 2025. All Rights Reserved by MedPath